PPP1R7

Across TCGA pan-cancer cohorts, PPP1R7 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated PPP1R7 data layer compared with 25 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in esophageal carcinoma (ESCA), where higher PPP1R7 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PPP1R7 expression acts as an unfavorable survival marker.

ESCA, MESO, and BRCA are the cancer types where PPP1R7 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ESCA	OS	Median	II,III,IV	0.117	0.703	<.001	36	view →
MESO	DFS	Median	III,IV	0.078	0.376	.012	9	view →
BRCA	DFS	Median	II,III,IV	0.321	0.889	<.001	6	view →
LIHC	DFS	Median	All	0.096	0.526	.023	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

PPP1R7–ESCA (OS)

Open the ESCA breakdown →